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ABSTRACT
Background
The presence of tumor-specific mutations in the cancer genome represents a potential
opportunity for pharmacologic intervention to therapeutic benefit. Unfortunately, many classes
of oncoproteins (e.g., transcription factors) are not amenable to conventional small-molecule
screening. Despite the identification of tumor-specific somatic mutations, most cancer therapy
still utilizes nonspecific, cytotoxic drugs. One illustrative example is the treatment of Ewing
sarcoma. Although the EWS/FLI oncoprotein, present in the vast majority of Ewing tumors, was
characterized over ten years ago, it has never been exploited as a target of therapy. Previously,
this target has been intractable to modulation with traditional small-molecule library screening
approaches. Here we describe a gene expression–based approach to identify compounds that
induce a signature of EWS/FLI attenuation. We hypothesize that screening small-molecule
libraries highly enriched for FDA-approved drugs will provide a more rapid path to clinical
application.
Methods and Findings
A gene expression signature for the EWS/FLI off state was determined with microarray
expression profiling of Ewing sarcoma cell lines with EWS/FLI-directed RNA interference. A
small-molecule library enriched for FDA-approved drugs was screened with a high-throughput,
ligation-mediated amplification assay with a fluorescent, bead-based detection. Screening
identified cytosine arabinoside (ARA-C) as a modulator of EWS/FLI. ARA-C reduced EWS/FLI
protein abundance and accordingly diminished cell viability and transformation and abrogated
tumor growth in a xenograft model. Given the poor outcomes of many patients with Ewing
sarcoma and the well-established ARA-C safety profile, clinical trials testing ARA-C are
warranted.
Conclusions
We demonstrate that a gene expression–based approach to small-molecule library screening
can identify, for rapid clinical testing, candidate drugs that modulate previously intractable
targets. Furthermore, this is a generic approach that can, in principle, be applied to the
identification of modulators of any tumor-associated oncoprotein in the rare pediatric
malignancies, but also in the more common adult cancers.
The Editors’ Summary of this article follows the references.
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A major challenge in pediatric oncology is the timely
development and testing of drugs for children with cancer.
Because the pediatric malignancies are rare, they are not an
industry priority for drug development. In addition, there is a
historical reluctance to test new drugs in children. In fact,
almost all therapies currently used in the treatment of
pediatric cancers were ﬁrst tested in adults. Despite this lack
of progress in treatment, signiﬁcant advances have been
made in understanding the molecular basis of pediatric
malignancies. Frequently, these tumors are associated with
tumor-speciﬁc somatic mutations generating oncoproteins
[1–3]. In principle, these oncoproteins represent unique,
tumor cell–speciﬁc targets for therapeutic development. In
practice, however, few oncoprotein-targeted drugs, partic-
ularly for the pediatric malignancies, have entered clinical
trial. Here lies a second challenge. Many of the identiﬁed
oncoproteins present in pediatric tumors, particularly those
involving transcription factors, are considered ‘‘undrug-
gable.’’ These targets have been largely ignored because there
is no obvious approach to pharmacologically inhibiting their
function. Traditional, biochemical small-molecule screens
might be directed against druggable downstream effectors of
these oncoproteins, but in most cases, such critical effectors
have yet to be identiﬁed.
The pediatric solid tumor Ewing sarcoma is one example of
these challenges. Ewing sarcoma treatment exempliﬁes the
problem of molecularly informed therapy lagging behind
identiﬁcation of a pathognomonic genetic lesion. Over ten
years ago, the translocation t(11;22)(q24;q12) was character-
ized and subsequently identiﬁed in over 80% of patients with
Ewing sarcoma, yet no oncoprotein-directed therapy has
been developed [2,4]. This translocation fuses the amino
terminus of the EWS protein to the DNA-binding domain of
the ETS transcription factor FLI. The resultant EWS/FLI
fusion protein is believed to function by transcriptionally
dysregulating target genes critical for tumor formation [5–7].
EWS/FLI is an attractive treatment target for Ewing
sarcoma because of its malignant cell speciﬁcity. Further-
more, experimental evidence indicates that EWS/FLI expres-
sion is essential for Ewing sarcoma tumor cells. In vitro
targeting of EWS/FLI with antisense oligodeoxynucleotides
and RNA interference (RNAi) inhibits Ewing sarcoma cell
viability, growth, and oncogenic transformation, supporting
EWS/FLI attenuation as a potential treatment modality [8–
14]. However, to date, Ewing therapy has largely consisted of
combinations of nontargeted cytotoxic agents. Event-free
survival at ﬁve years for patients with metastatic disease is
only 20% [15,16], and curative therapy does not yet exist for
patients whose disease recurs rapidly following therapy for
localized disease.
To overcome the current limitations to small-molecule
library screening, we developed gene expression-based high-
throughput screening (GE-HTS) [17]. GE-HTS uses gene
expression signatures as surrogates for cellular states. First,
gene expression–based signatures of the biological states of
interest (i.e., ‘‘state A’’ versus ‘‘state B’’) are deﬁned using
genome-wide gene expression proﬁling. Next, an assay is
developed (as described below) for the high-throughput, low-
cost measurement of the signature. Then, a small-molecule
library is screened for compounds that induce a change from
the ‘‘state A’’ to the ‘‘state B’’ signature. Unlike traditional
phenotype-based screens, GE-HTS does not require develop-
ment of specialized assays. The gene expression signature
deﬁnition, ampliﬁcation, and detection are generic. Further-
more, a priori knowledge of a target is not needed. The gene
expression signature serves as a surrogate for the biological
state in question. The method is thus well suited for discovery
of modulators of oncogenic transcription factors in which the
mutant transcription factor’s transforming mechanism is not
known.
We hypothesized that drugs may already exist for the
treatment of Ewing sarcoma, but tools to prioritize candi-
dates for clinical testing have been lacking. We therefore
performed a GE-HTS-based small-molecule library screen to
identify modulators of EWS/FLI activity in Ewing sarcoma
and focused our efforts on collections of bioactive com-
pounds that contain FDA-approved drugs.
Methods
Cell Culture
The Ewing sarcoma cell lines A673, EWS502, and TC71
were grown as previously described [18]. The EWS502 line was
originally developed by Jonathan Fletcher’s laboratory and is
reported to have a type 1 EWS/FLI fusion (J. Fletcher,
personal communication). Its growth arrests in response to
EWS/FLI knockdown and requires both NKX2.2 and NR0B1
for growth and transformation [14,19]. EWS502 harbors the
previously reported C135F mutation in the tumor suppressor
p53 [20,21]. Tet-A673 cells harboring an inducible EWS/FLI
cDNA were also previously described [14]. TC32 Ewing
sarcoma cells were grown in RPMI 1640 (Cellgro, http://www.
cellgro.com) with 10% FBS (Sigma, http://www.sigmaaldrich.
com), penicillin-streptomycin (Cellgro), and glutamine (Gib-
co, http://www.invitrogen.com). The carcinoma cell lines
A549, HCT116, SW480, and T47D were all purchased from
the American Type Culture Collection (ATCC, http://www.
atcc.org) and grown in Ham’s F-10 (A549) (Cellgro), RPMI
1640 (HCT116), and DMEM (SW480 and T47D) (Cellgro)
supplemented with penicillin-streptomycin and 10% FBS.
HL-60 and U937 cells were purchased from ATCC and grown
in RPMI 1640 with 10% FBS and 1% penicillin-streptomycin.
Growth analysis using a serial passage 3T10 assay was
performed by plating 1 3 10
6 cells in a 10-cm tissue culture
dish every 3 d and counting the resultant number of cells 3 d
later over 15 d. In some samples, 30 nM or 60 nM cytosine
arabinoside (ARA-C) was included in the culture medium.
Soft agar assays were performed essentially as previously
described, except that 30 nM or 60 nM ARA-C was included
in the agar layers and medium in some samples [18].
Retroviruses
The retroviral RNAi vectors EF-2-RNAi and luc-RNAi were
previously described [14]. Retroviral production and infec-
tion were performed as previously described [18]. Following
retroviral infection, cells were selected and maintained in 2
lg/ml of puromycin (Sigma).
Immunodetection
Cells were lysed in RIPA buffer (10 mM Tris-Cl [pH 7.6],
100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium
deoxycholate, and 0.1% SDS) with protease inhibitor (Com-
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Diagnostics, http://www.roche.com), resolved by electropho-
resis on 10% Tris-HCl precast Ready Gel (BioRad Laborato-
ries, http://www.bio-rad.com), and transferred to
nitrocellulose membranes (Schleicher and Schuell, http://
www.schleicher-schuell.com) for whole cell lysates. All pro-
teins were detected using chemiluminescence and antibodies
to FLI-1 (sc-356, Santa Cruz Biotechnology, http://
www.scbt.com), pan-actin antibody (ACTN05, NeoMarkers,
http://www.labvision.com), acetyl-histone H3 (06–599, Upstate
Cell Signaling Solutions, http://www.upstate.com), Sp3 (07–
107, Upstate Cell Signaling Solutions), BTF3 (38–6100, Zymed
Laboratories, Invitrogen Immunodetection), and YY1
(AP2517a, Abgent, http://www.abgent.com).
Marker Gene Selection
The Affymetrix U133A datasets used for marker gene
identiﬁcation were previously reported [14] and are available
at http://www.broad.mit.edu/cancer/Ewing_ARA-C. The ﬁrst
dataset was derived from A673 Ewing sarcoma cells express-
ing one of two different EWS/FLI retroviral knockdown
constructs (EF-2-RNAi or EF-4-RNAi, herein called ‘‘EWS/
FLI-knockdown’’) or a control construct directed against
luciferase (herein called ‘‘EWS/FLI-expressing’’). GeneChip
MAS5 software (Affymetrix, http://www.affymetrix.com) was
used for preprocessing of the raw data, and all scans within an
experiment were scaled to the array with the median overall
microarray intensity. Thresholds were set to a minimum value
of 10 and a maximum value of 16,000, and a variation ﬁlter of
5-fold minimum and 50 minimum absolute difference was
applied. We used the signal-to-noise ratio to rank order the
genes that distinguish ‘‘EWS/FLI-expressing’’ from ‘‘EWS/FLI-
knockdown’’ and then permutation testing to identify genes
that distinguish these states with a p , 0.05 [22]. We next
identiﬁed genes with at least a 2.5-fold difference between the
two classes of interest and an expression value of less than 25
in one of the two states. We then evaluated these genes in an
EWS/FLI-inducible rescue dataset. This dataset was generated
from Tet-A673 inducible Ewing sarcoma cells expressing the
EF-2-RNAi construct to knock down endogenous EWS/FLI
expression and subsequently induced to express the exoge-
nous EWS/FLI cDNA. Data points were collected at various
times after induction. Through a comparison of the stable
knockdown and inducible rescue datasets, we selected 14
genes that were well correlated with EWS/FLI expression in
both datasets. We included glyceraldehyde-3-phosphate dehydro-
genase (GAPD) as a control for well-to-well variability, as it
demonstrated a stable expression pattern in all conditions.
We also included a probe for FLI1 to monitor effective
knockdown in the positive control wells with EWS/FLI-
directed retroviral RNAi constructs.
Small-Molecule Library Screening
Cell and compound addition. A673 cells were plated in 384-
well tissue culture plates in 50 ll of medium at 6,000 cells/well.
The EWS/FLI short hairpin RNA (shRNA) infected A673
controls (EF-2-RNAi) were grown at 8,000 cells/well. The
following controls were included on each 384-well screen
plate: medium only (16 wells), A673 cells with DMSO vehicle
(eight wells), and EF-2-RNAi (eight wells). In addition, two
plates with controls exclusively were included in the screen:
medium (44 wells), A673 þ DMSO (154 wells), and EF-2-RNAi
(154 wells).
Compounds were added at a ﬁnal approximate concen-
tration of 20 lM in DMSO and incubated for 3 d at 37 8C with
5% CO2. We screened in triplicate the National Institute of
Neurological Disorders and Stroke small-molecule collection
containing 1,040 compounds (http://www.broad.harvard.edu/
chembio/platform/screening/compound_libraries/ninds.
htm). A total of three-quarters of the compounds in this
collection of characterized bioactive molecules are FDA
approved.
RNA extraction and reverse transcription. After 3 d of
chemical incubation, 40 ll of medium was removed from the
wells with a Multimek robot (Beckman Coulter, http://www.
beckmancoulter.com). Cells were then lysed with 25 ll of lysis
buffer for 30 min at room temperature. Lysate was trans-
ferred to a 384-well oligo-dT coated plate and incubated for 1
h at room temperature. Reverse transcription was carried out
in a 5-ll MMLV reaction (Pierce, http://www.piercenet.com)
for 1.5 h at 37 8C. Lysis buffers and 384-well oligo-dT plates
were purchased from RNAture (Hitachi Chemical, http://
www1.qiagen.com).
Ligation-mediated ampliﬁcation. After 1.5 h, unbound
material was removed by inverting the plate onto an
absorbent towel and spinning in the centrifuge. Signature
gene-speciﬁc oligonucleotide probes were hybridized to the
cDNA using 2 nM of each probe (16 probe pairs in total) and
Taq ligase buffer (New England Biolabs, http://www.neb.com)
in a 5-ll reaction. Upstream probes contained the T7 primer
site, Luminex-designed FlexMap barcode tag (24 nt), and
gene-speciﬁc sequence (20 nt). Downstream probes were
phosphorylated at the 59 end and contained gene-speciﬁc
sequence (20 nt) followed by the T3 primer site. Gene-speciﬁc
sequence was chosen such that the 20-base-pair sequences of
the upstream and downstream probes contain similar base
composition, minimal repeats, and C-G or G-C juxtaposing
nucleotides (Table S1). Hybridization was performed at 95 8C
for 2 min followed by 50 8C for 1 h. Excess probe was then
spun out. Probes were ligated in a 5-ll reaction using Taq
DNA ligase (New England Biolabs) at 45 8C for 1 h followed by
incubation at 65 8C for 10 min. Excess ligation mix was spun
out. The ligated products were ampliﬁed with the universal
T3 primer (59-ATT AAC CCT CAC TAA AGG GA-39) and
universal biotinylated T7 primer (59-TAA TAC GAC TCA
CTA TAG GG-39) (Integrated DNA Technologies, http://www.
idtdna.com) using HotStarTaq DNA Polymerase (Qiagen,
http://www1.qiagen.com) in a 7-ll reaction system. PCR was
performed at 92 8C for 9 min, followed by 39 cycles of
denaturation at 92 8C for 30 s, annealing at 60 8C for 30 s, and
extension at 72 8C for 30 s.
Amplicon detection. xMAP Multi-Analyte COOH micro-
spheres (Luminex, http://www.luminexcorp.com) (2.5 million)
were coupled to complementary FlexMap barcode sequence
(4 lM) with 2.5 ll of 10 mg/ml 1-ethyl-3-(3-dimethylamino-
propyl)-carbodiimide hydrochloride (EDC) (Pierce) in 25 ll
0.1 M 2-(N-morpholino) ethanesulfonic acid (pH 4.5) (MES)
buffer (Sigma). This 30-min coupling reaction was then
repeated. Microspheres were then washed sequentially with
0.02% Tween-20, 0.1% SDS, and TE (pH 8), and resuspended
in 50 ll of TE (pH 8). Next, a ligation-mediated ampliﬁcation
(LMA) sample was hybridized to microspheres by incubating
2,500 of each microsphere in 18 ll of 1.53 TMAC (4.5 M
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mM Tris-HCl [pH 8], and 6 mM EDTA [pH 8]) and 5 llo fT E
(pH 8) at 95 8C for 2 min and then 45 8C for 1 h. For
detection, the sample was incubated with 10 ll of streptavi-
din-phycoerythrin (SA-PE) (Invitrogen) (1% SA-PE in 13
TMAC [3 M tetramethylammonium chloride], 0.1% N-lauryl
sarcosine, 50 mM Tris-HCl [pH 8], and 4 mM EDTA [pH 8])
for 5 min at 45 8C and then washed once and resuspended
with 13 TMAC. Dual-color ﬂuorescence was detected with a
Luminex high-throughput detection instrument. A minimum
of 100 events was recorded for each microsphere, and median
ﬂuorescent intensities computed.
Hit identiﬁcation. The median ﬂuorescence level for each
gene (where each gene was represented by a particular bead
color) from the Luminex detector was used as a measure of
the gene’s expression. To maximize consistency between and
within plates, we normalized genes by using the expression
ratio between each gene and GAPD. Next, ﬁltering was
performed to eliminate ‘‘dead’’ wells from further analysis
where GAPD expression levels were used as a proxy for cell
viability. Because ratios with GAPD as the denominator were
used for subsequent analysis, we needed to eliminate wells
where GAPD was nominally zero. Forming a ratio with such a
low denominator could potentially falsely ﬂag a well where
the cells were merely dead or dying. For our ﬁltering level, we
used the mean minus two times the standard deviation of the
untreated A673 control wells. For this screen, 128 out of 3,840
compound wells were ﬁltered. After ﬁltering, we used a
‘‘summed score’’ metric to identify candidate modulators of
EWS/FLI. This metric combined expression ratios by sum-
ming them with a sign determined by the expected direction
of regulation as determined from the EWS/FLI shRNA
samples. Compounds were ranked for follow-up according
to the total of the summed score from the three replicates.
Evaluation of Whole Genome Effects
Gene set enrichment analysis. To test ARA-C’s affects on
the EWS/FLI expression program, an expanded signature for
EWS/FLI knockdown (Table S2) was created from the EWS/
FLI RNAi dataset and tested for enrichment using the gene
set enrichment analysis (GSEA) method with publicly
available software (http://www.broad.mit.edu/gsea) [23]. A
gene set for EWS/FLI knockdown was created by thresholding
(10 minimum and 16,000 maximum) and ﬁltering (5-fold
minimum variation and 50 minimum absolute difference),
which resulted in 1,460 genes that passed ﬁltering. All genes
that distinguished EWS/FLI shRNA versus the luciferase
controls (t-test p , 0.01 [74 genes up-regulated and 93 genes
down-regulated with EWS/FLI knockdown]) and conﬁrmed to
have a consistent direction of change in the inducible EWS/
FLI dataset (66 genes up-regulated and 77 genes down-
regulated with EWS/FLI knockdown) were identiﬁed. The 66-
gene EWS/FLI up-regulated gene set was tested for enrich-
ment in sample sets formed out of the 17 DMSO-treated A673
samples versus the combined 3-d and 5-d compound-treated
sets (typically six samples each for ARA-C, doxorubicin, and
puromycin). The enrichment of the members of the EWS/FLI
gene set was measured by the enrichment score, and
statistical signiﬁcance was determined using permutation
testing (2,500 permutations). The results of the GSEA are
summarized in Table S3. Sample and cel ﬁle names are listed
in Table S4. Raw data are available at http://www.broad.mit.
edu/cancer/Ewing_ARA-C or at GEO (Gene Expression
Omnibus, http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.
cgi) series record GSE6930.
Sample preparation. RNA was extracted with Trizol per the
manufacturer’s protocol (Invitrogen) and prepared for
hybridization to Affymetrix high-throughput arrays. We used
2 lg of RNA for target preparation as per the Affymetrix
Gene Chip Automated Station (GCAS) protocol (Early Access
User manual version 1.0) and 3.5 lg of cRNA hybridized to
Affymetrix 96-well Gene Chip HT arrays.
Viability Assay
Viability experiments were performed in 96-well format in
replicates of four using the Promega Cell-Titer Glo ATP-
based assay per the manufacturer’s instructions (http://www.
promega.com). Cells were evaluated at 0, 3, and 6 d with ARA-
C in a 2-fold dilution from 10 lM down to 78 nM versus
water-control–treated cells. The concentration at which cell
viability was reduced to 50% of water-treated controls (EC50)
was determined. Values for EC50 were calculated by inter-
polating a polynomial ﬁt to the measured viability data.
Curve ﬁtting was performed in MATLAB (http://www.
mathworks.com) using the least-squares curve-ﬁtting function
(polyﬁt). Model order for the polynomial was set to n¼3. The
EC50 value was found by interpolating the curve for the value
of 50 with the MATLAB one-dimensional interpolation
function (interp1).
Real-Time Reverse Transcriptase PCR
Total RNA was isolated using TRIZOL reagent (Invitrogen)
from A673 cells treated with vehicle, ARA-C 170 nM, and
ARA-C 340 nM for 3 d. cDNA was synthesized from 1 lgo f
total RNA using SuperScript III Reverse Transcriptase
(Invitrogen) and oligo d(T)16 primers in a 20-ll reaction
system. cDNA (1 ll) was analyzed in the real-time quantitative
PCR reactions prepared with TaqMan Universal Master mix
(Applied Biosystems, http://www.appliedbiosystems.com).
Each sample was assessed in triplicate to ensure reproduci-
bility of the quantitative measurements. GAPD expression was
evaluated for each sample as a control for total RNA. Primers
and probes for real-time reverse transcriptase PCR were
obtained from Applied Biosystems Assays: number 302414 for
FLI and number 402869 for GAPD.
Apoptosis Analysis
We cultured 1.5 3 10
6 cells with and without ARA-C at the
following concentrations, 170 nM, 340 nM, and 680 nM ARA-
C. As a control for apoptosis, cells were also treated with 3.7
lM puromycin. Cells were treated for 3 d. Annexin V FITC/PI
staining was performed using the Annexin V: FITC Apoptosis
Detection Kit I (BD Pharmingen, http://www.bdbiosciences.
com). Cells were analyzed by ﬂow cytometry with a FACScan
ﬂow cytometer (Becton Dickinson, http://www.bd.com) and
CELLQuest analytical software.
Xenograft Studies
A673 cells were infected with retroviruses expressing a
luciferase–neomycin resistance gene fusion protein and
selected with G418 [14]. Following selection, 1 3 10
6 cells
were injected into the ﬂanks of NCr nude mice, and A673-
luciferase–positive xenografts were established for 2–3 wk
with tumor burden monitored by bioluminescence imaging.
Mice with logarithmically growing tumors were treated with
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doses or vehicle control. We treated nine mice per condition.
Mice were imaged weekly using a Xenogen IVIS 100 imaging
system, per the manufacturer’s directions (http://www.
xenogen.com). Student’s t-test (two-tailed assuming samples
with equal variance) was used to compare tumor burden
across the two cohorts. Animal experiments were performed
following approval from the Dana-Farber Cancer Institute
Animal Care and Use Committee (http://www.dfci.harvard.
edu).
Results
EWS/FLI Off Marker Gene Signature Identified for GE-HTS
The GE-HTS screening approach enables identiﬁcation of
small molecules that induce a change in expression signature
from the EWS/FLI on state to the EWS/FLI off state. We ﬁrst
needed to design a signature of EWS/FLI loss of function.
Accordingly, we established the transcriptional proﬁle of
A673 Ewing sarcoma cells in the presence or absence of an
shRNA directed against the endogenous EWS/FLI transcript,
as described in detail elsewhere [14]. A673 cells were chosen
because knockdown of EWS/FLI results in loss of tumor-
igenicity in soft agar and murine xenografts, but only
minimally alters their normal growth in tissue culture. As
such, the EWS/FLI knockdown signature is more likely to
reﬂect EWS/FLI loss of function, rather than a general
signature of growth arrest or apoptosis, as is observed in
other Ewing cell lines [14]. A second challenge was controlling
for the off-target effects of shRNA in the deﬁnition of an
EWS/FLI signature. To address this, we used an EWS/FLI
rescue system in which loss of oncogenic transformation with
shRNA could be rescued by ectopic expression of an EWS/FLI
cDNA lacking the 39 UTR to which the EWS/FLI shRNA was
directed [14].
We ﬁrst designed a signature for use in the GE-HTS
platform. Signature genes were selected based on the
following criteria: (i) statistically different expression in the
EWS/FLI knockdown versus control A673 cells (at p , 0.05
based on permutation testing); (ii) fold-change over 2.5; (iii)
nearly undetectable expression in one of the two conditions;
and (iv) reversion of expression with induction of the EWS/
FLI rescue construct. We selected 14 genes meeting these
criteria (Figure 1). GAPD was included as a control for well-to-
well variability in the screen because of its stable expression
across the dataset. FLI1 was included to demonstrate EWS/FLI
knockdown in positive control wells with EWS/FLI directed
shRNA. The ﬁnal signature thus constituted 16 genes.
GE-HTS Overview: LMA with Fluorescent Bead Detection
To measure the EWS/FLI signature in the setting of a small-
molecule screen, we converted the 16-gene signature to a low-
cost, high-throughput format. Our previous implementation
of the GE-HTS method involved multiplexed reverse tran-
scriptase-PCR followed by detection by mass spectrometry
[17]. That method, however, is limited to signatures of
approximately six genes. To overcome this limitation, we
developed a new approach in which multiplexed LMA
products are detected by bead-based ﬂow cytometry. The
LMA/bead-based detection protocol is described in detail
elsewhere [24–26]. Brieﬂy, mRNAs are captured on oligo-dT
coated 384-well plates and reverse transcribed to generate
ﬁrst strand cDNA. Locus-speciﬁc oligonucleotides (oligos)
corresponding to the 16 signature genes are then annealed to
the cDNA template. The oligos are designed such that (i) the
primer pairs abut each other, thereby facilitating subsequent
ligation, (ii) one of the oligos incorporates a unique barcode
sequence facilitating subsequent bead capture, and (iii) both
oligos incorporate a common ﬂanking sequence facilitating
PCR ampliﬁcation using a single set of PCR primers. One of
the PCR primers is biotinylated to facilitate detection (Figure
2A). This ampliﬁcation strategy enables the simultaneous
ampliﬁcation of the signature transcripts in a highly
reproducible manner that is faithful to the abundance of
the starting mRNAs [26]. Following PCR ampliﬁcation, the
LMA products are hybridized to beads coupled to capture
probes complementary to the LMA barcode sequence. Then,
staining with streptavidin–phycoerythrin is performed. The
use of beads of 16 different colors (each corresponding to a
different barcode capture probe) facilitates subsequent
quantitation of the LMA products by ﬂow cytometry. The
color of the bead denotes the identity of the signature
transcript, and the phycoerythrin intensity denotes the
transcript’s abundance (Figure 2A).
ARA-C Identified as Top Hit in GE-HTS for Modulators of
EWS/FLI
We screened in triplicate the National Institute of Neuro-
logical Disorders and Stroke bioactive small-molecule library
containing 1,040 small molecules, including many FDA-
approved drugs. A673 cells were incubated with one
compound per well for three days. A marker gene summary
score was calculated for each of the small molecules in the
screen and compared to that of the shRNA directed against
EWS/FLI versus parental A673 cells. ARA-C, a nucleoside
analog known to inhibit DNA synthesis, was identiﬁed as the
top hit scoring highly in all three replicates (Figure 2B).
Repeat evaluation of the marker genes in A673 cells after
ARA-C treatment conﬁrmed induction of the EWS/FLI off
signature (Figure S1). The library did not contain compounds
such as vincristine, doxorubicin, or ifosfamide, agents
currently used in the treatment of Ewing sarcoma. However,
it did contain 22 cytotoxic agents, none of which scored as
positives in the screen. Importantly, ARA-C did not elicit a
‘‘pseudo’’ EWS/FLI off signature in ARA-C-responsive, EWS/
FLI-negative, acute myeloblastic leukemia (AML) cell lines
(Figure S2), indicating that all cells exposed to ARA-C do not
nonspeciﬁcally regulate the EWS/FLI signature.
ARA-C Induces Whole-Genome Changes Consistent with
EWS/FLI Knockdown
To determine whether ARA-C induces a whole genome
program consistent with EWS/FLI attenuation, or merely
alters the expression of the marker genes selected for the
EWS/FLI off signature, we evaluated genome-wide expression
changes associated with ARA-C using GSEA [23]. GSEA is a
nonparametric analytical approach used to determine
whether the members of a set of genes of interest (e.g., genes
associated with EWS/FLI off) tend to occur toward the top of a
ranked list of genes corresponding to a class distinction (e.g.,
vehicle-treated versus ARA-C-treated A673 cells). In other
words, is the list of genes that distinguish vehicle- versus ARA-
C-treated A673 cells enriched for those genes whose
expression changes with knockdown of EWS/FLI? We ex-
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distinction to be found at the top of such a list and those
unrelated to be randomly distributed throughout. Our EWS/
FLI shRNA dataset was used to create an expanded list of
EWS/FLI off marker genes (Table S2). A total of 143 genes (66
up-regulated and 77 down-regulated) distinguished EWS/FLI
shRNA from the luciferase controls (p , 0.01) and were at
least partially reverted by the EWS/FLI rescue construct. A673
cells were treated with ARA-C or vehicle in triplicate and
expression proﬁled at 24 h, 3 d, and 5 d. ARA-C regulated the
expression of the EWS/FLI gene set at days 3–5 (p ¼ 0.04) but
not at 24 h of treatment at the EC50 (dose at which viability is
50% of vehicle-treated cells) (Figures 2C and S3A–S3D).
To exclude the possibility that ARA-C’s modulation of the
EWS/FLI signature was simply a nonspeciﬁc response to
treatment with all cytotoxic agents, we asked whether other
compounds known to kill Ewing sarcoma cells would induce
the EWS/FLI off genome-wide expression pattern. Experi-
ments were performed in triplicate. Puromycin treatment at
its EC50 did not (Figures 2C and S3E–S3H). Thus, inhibition
of cell viability alone does not induce the whole-genome
effects of EWS/FLI modulation, suggesting that ARA-C has a
more speciﬁc effect on EWS/FLI attenuation. As with ARA-C
treatment, doxorubicin, an agent currently used to treat
patients with Ewing sarcoma, did recapitulate the EWS/FLI off
signature (p ¼ 0.01) (Figures 2C and S3I–S3L) by three days.
Doxorubicin was not in the National Institute of Neurological
Disorders and Stroke small-molecule library.
ARA-C Decreases EWS/FLI Protein Levels
Because the GE-HTS approach to screening does not
assume prior knowledge of the target of active small
molecules, ARA-C’s modulation of EWS/FLI activity could
occur via many possible mechanisms. For example, it might
attenuate EWS/FLI by decreasing EWS/FLI transcript or
protein, by interfering with EWS/FLI binding to DNA, or by
interfering with downstream effectors of EWS/FLI. Quantita-
tive PCR for EWS/FLI transcript abundance indicated no
decrease in EWS/FLI mRNA levels with ARA-C treatment, a
ﬁnding similar to that of the original screen. Rather, a dose-
responsive increase in EWS/FLI transcript was observed
(Figure 3A). In contrast, ARA-C treatment at the EC50
resulted in a marked decrease in EWS/FLI protein abundance
by 48 h as measured by Western blotting (Figure 3B).
Figure 1. EWS/FLI Off Marker Gene Selection
(A) EWS/FLI Western blot analysis with anti-FLI antibody confirms reduction in protein levels with infection of the A673 Ewing sarcoma cell line with
retrovirus containing an shRNA construct directed against EWS/FLI (EF-2-RNAi) compared to a control with RNAi directed against EWS/ERG (ERG-RNAi)
which is not expressed in A673 cells. Actin is shown as a loading control.
(B) Gene expression profiling was performed with shRNA designed against a luciferase control (four replicates) and in duplicate against two different
shRNA constructs against EWS/FLI. Using the signal-to-noise ratio, the genes distinguishing luciferase from EWS/FLI directed RNAi were identified and
then prioritized for a fold change of at least 2.5 and a baseline level of expression less than 25 in one of the states. These genes were then evaluated in
an inducible EWS/FLI rescue system. Exogenous EWS/FLI was induced over 72 h in A673 cells with EWS/FLI knockdown by shRNA, and samples
evaluated in duplicate at multiple time points. The EWS/FLI off signature genes are shown in the heat map. Samples are shown in columns and genes in
rows. Blue represents poorly expressed genes, and red depicts highly expressed genes.
doi:10.1371/journal.pmed.0040122.g001
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ARA-C Identified as an EWS/FLI ModulatorFigure 2. GE-HTS Identifies ARA-C as the Top Hit Inducing an EWF/FLI Off Signature
(A) GE-HTS utilizes LMA with fluorescent microsphere detection of PCR amplicons. Cells are lysed, and lysate transferred to a 384-well plate coated in
oligo-dT. Reverse transcription is performed and then probes hybridized to the cDNA. The upstream probe contains a universal T7 sequence, barcode
capture sequence (B.C.), and gene-specific sequence (G.S.S.). The downstream probe contains gene-specific sequence and T3 universal sequence. The
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ARA-C Identified as an EWS/FLI ModulatorImportantly, abundance of housekeeping genes, such as Actin
and GAPD, and nuclear proteins, such as the transcription
factors Sp3, YY1, and BTF3 did not decrease with ARA-C
treatment (Figure S4). As observed with the analysis of
genome-wide expression effects, treatment of A673 cells with
puromycin at equipotent dosing did not decrease EWS/FLI
protein levels, suggesting that loss of EWS/FLI is not an
inevitable consequence of inhibiting A673 viability (Figure
3C). Interestingly, doxorubicin did diminish EWS/FLI protein
levels, likely explaining its modulation of the EWS/FLI gene
expression signature (Figure 3C). Similarly, the mTOR
inhibitor rapamycin, previously reported to decrease EWS/
Figure 3. ARA-C Decreases EWS/FLI Protein Levels But Not Transcript
(A) Real-time reverse transcriptase-PCR reveals increase in EWS/FLI transcript. EWS/FLI transcript was detected after ARA-C at the 3-d EC50 (170 nM) and
2-fold and 4-fold above. EWS/FLI expression is depicted relative to vehicle treated parental A673 cells. Error bars show the standard deviation across
three replicates.
(B) Western blot analysis with anti-FLI antibody confirms a marked reduction in protein levels with treatment of the A673 Ewing sarcoma cell line with
ARA-C at 48 and 72 h at the 3-d ARA-C EC50 (170 nM), and 2-fold and 4-fold above (340 and 680 nM, respectively). Actin is shown as a loading control.
(C) Western blot analysis with anti-FLI antibody confirms no reduction in EWS/FLI protein with 3 d of puromycin treatment at the 3-d EC50 (90 nM) or 2-
fold above. With doxorubicin, there is a reduction in EWS/FLI protein levels with 3-d treatment at the 3-d EC50 (60 nM) and 2-fold above (120 nM). Actin
is shown as a loading control.
doi:10.1371/journal.pmed.0040122.g003
probes are then ligated and PCR performed with a universal, biotinylated T7 primer (FT7b) and a universal T3 primer (RT3). Amplicons are captured with
fluorescent microspheres coupled to capture probes containing sequence complementary to the barcode capture sequence (C.B.C). Amplicons are
stained with streptavidin-phycoerythrin (SA-PE) and then quantified with dual color flow cytometry. Bead color is used to identify each gene, and the
amount of phycoerythrin fluorescence measures the quantity of transcript.
(B) Distribution of the summed score for the EWS/FLI off marker genes is shown. Gray indicates the distribution for the A673 vehicle control samples,
black indicates the distribution for the EWS/FLI shRNA controls (EF-2-RNAi), and red for the 1,040 compounds screened in triplicate. The black arrows
indicate the location of each of the replicates of ARA-C treatment within the distribution.
(C) GSEA results for the set of EWS/FLI shRNA up-regulated genes confirmed in the inducible EWS/FLI dataset (66 genes) tested at 3 and 5 d at the EC50
for ARA-C (170 nM), puromycin (90 nM), and doxorubicin (60 nM). The running enrichment score, generated by the markers after they have been
ordered with the phenotype of interest, is shown in red. The position of the genes in the gene set is shown as a blue line (‘‘hits’’). The ranking scores for
the genes are shown in gray. The amount of enrichment is estimated by the maximum deviation from zero of the enrichment score, and statistical
significance was determined using permutation testing (2,500 permutations).
doi:10.1371/journal.pmed.0040122.g002
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ARA-C Identified as an EWS/FLI ModulatorFLI protein in Ewing sarcoma cell lines, induced the EWS/FLI
off signature as assessed by our GE-HTS assay [27,28].
ARA-C Inhibits Cell Viability in Multiple Ewing Sarcoma
Cell Lines
We evaluated the effects of ARA-C on cell viability in A673
cells and in three other Ewing sarcoma cell lines known to
contain the EWS/FLI translocation (EWS502, TC32, and TC71)
with an ATP-based assay (Figure 4A; Table S5). The EC50
ranged from 80 nM to 380 nM at 3 d (mean¼180 nM) and 50
nM to 280 nM at 6 d (mean¼110 nM), levels easily achievable
in humans in vivo, and consistent with prior reports [29]. In
fact, peak serum levels of 40 lM are routinely attainable with
ARA-C treatment of patients with AML [30]. Furthermore,
treatment with ARA-C induced an annexin V-positive FACS
proﬁle, consistent with apoptosis (Figure 4B).
Ewing sarcoma cell lines were found to be particularly
sensitive to ARA-C, compared to non-Ewing cell lines, in
which the 3 d ARA-C EC50 was in most cases signiﬁcantly
higher: colorectal adenocarcinoma SW480 (15.1 lM), human
mammary adenocarcinoma T47D (40.8 lM), lung adenocar-
cinoma A549 (530 nM), and colorectal adenocarcinoma
HCT116 (250 nM). These data suggest that not all malignant
cell lines respond equally well to ARA-C treatment (Figure
4C; Table S5).
ARA-C Abrogates Anchorage-Independent Growth
It had previously been reported that EWS/FLI RNAi
knockdown in A673 cells abrogates anchorage-independent
growth, one of the hallmarks of oncogenic transformation
[14]. We sought to determine whether ARA-C would pheno-
copy this effect in A673 cells. We treated A673 cells with
ARA-C at doses below the 3 d EC50 (30 and 60 nM) and
evaluated colony formation in soft agar. At 30-nM ARA-C,
cells were limited in their ability to form colonies. A total of
60 nM ARA-C nearly completely abrogated colony formation
(Figure 5A). It is possible that loss of colony formation is
merely a result of ARA-C inhibition of A673 cell viability
rather than independent inhibition of transformation. In
order to address this issue, we simultaneously performed a
3T10 serial passage growth assay to evaluate effects of these
conditions on A673 doubling time (Figure 5B). A total of 15 d
of treatment with ARA-C at 30 and 60 nM decreased mean
population doubling time by 18% and 32%, respectively,
compared to parental controls. Thus, while we see only
modest effects of low dose ARA-C on cell growth, we see
dramatic effects on transformation.
ARA-C Inhibits Tumor Growth in Xenograft Model of
Ewing Sarcoma
A xenograft model of Ewing sarcoma was used to evaluate
the effects of ARA-C on in vivo tumor growth. A673 cells were
engineered to express ﬁreﬂy luciferase, and tumor burden
was monitored by in vivo bioluminescence imaging as
previously described [14]. After inoculation of cells in the
ﬂanks of nude mice, tumors were allowed to establish for 2–3
wk. Mice with logarithmically growing tumors were divided
into cohorts and treated with either systemic ARA-C at 50
mg/kg daily for four doses or vehicle control. Whereas
vehicle-treated animals had tumors that continued to grow
logarithmically, ARA-C-treated animals had signiﬁcantly
reduced tumor growth or tumor regression (Figure 6A and
6B). There was no signiﬁcant effect on body weight in ARA-C
treated animals, suggesting no signiﬁcant systemic toxicity at
this dose (unpublished data).
Discussion
Little has changed in the treatment of patients with Ewing
sarcoma over the past ten years, particularly for those with
metastatic or relapsed disease. Furthermore, no current
therapies target the known molecular lesion present in the
vast majority of Ewing tumors, the EWS/FLI oncoprotein.
One recent advance for patients with localized disease, the
addition of ifosfamide and etoposide to the backbone of
Ewing therapy (doxorubicin, vincristine, and cyclophospha-
mide), suggests that existing drugs might improve cure rates
for patients with Ewing sarcoma [15]. However, a challenge
has been the identiﬁcation and prioritization of candidate
therapies among the over 1,300 known FDA-approved drugs.
A second challenge has been the difﬁculty in identifying,
with traditional small-molecule library screening, modula-
tors of oncoproteins involving transcription factors such as
EWS/FLI. The work presented here addresses these two
challenges. A gene expression–based approach was used to
screen a small-molecule library, enriched for FDA-approved
drugs (;7 5 0o ft h e1 , 3 0 0F D A - a p p r o v e dd r u g s ) ,f o r
compounds that attenuate EWS/FLI. ARA-C was identiﬁed
as the top hit.
One of the powers of the GE-HTS approach lies in the use
of multigene signatures to represent a complex biological
state change. The individual signature genes are not
required to be immediate transcriptional targets of the
oncoprotein in question, but rather genes that are faithfully
dysregulated by it. As such, the EWS/FLI off signature genes
may be direct or indirectly regulated by EWS/FLI. Previously
reported, putative direct EWS/FLI target genes are not
represented in our EWS/FLI off signature, possibly in part
because the signature genes are not direct targets of EWS/
FLI. However, this difference likely also reﬂects a difference
in the cell system used in our screen. Because the true cell of
origin for Ewing sarcoma is unknown, many of the
previously reported EWS/FLI target genes were identiﬁed
in heterologous cell systems, such as NIH3T3 cells. As noted
in Smith et al. [14], a discrepancy can be seen between
identiﬁed EWS/FLI targets in heterologous systems versus
those identiﬁed in Ewing sarcoma, itself. For example, Smith
et al. found that MYC, ID2, MFNG, KRT115, UBE2C, CYP2FI,
and CDKN1C were not signiﬁcantly altered as previously
reported in the literature based upon heterologous systems
[14]. The use of human Ewing sarcoma cell lines rather than
heterologous systems to deﬁne the signature of EWS/FLI off
should more closely recapitulate the activity of EWS/FLI in
human disease.
ARA-C was the top hit conﬁrmed to induce both the EWS/
FLI off signature and broader gene expression changes
associated with the EWS/FLI off state. These expression
changes are secondary to ARA-C induced decrease in EWS/
FLI protein. As with EWS/FLI knockdown, ARA-C treatment
inhibits transformation and cell viability. Thus, it seems likely
that the biological effects of ARA-C are, at least in part,
related to the decrease in EWS/FLI protein. However, ARA-C
has a more profound effect on A673 cell growth and
apoptosis than does EWS/FLI knockdown via RNAi. This
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ARA-C Identified as an EWS/FLI ModulatorFigure 4. ARA-C Inhibits Cell Viability and Induces Cell Death
(A) Four different Ewing sarcoma cell lines expressing the EWS/FLI translocation were treated with ARA-C in a dose-response series for 6 d. Cell viability
was evaluated with an ATP-based assay and plotted relative to control cells. Error bars show standard deviation across four replicates.
(B) A673 cells were treated with vehicle (negative control) or puromycin (positive control) or ARA-C at 170, 340, and 680 nM for 3 d, stained with
annexin V-FITC and propidium iodine, and evaluated by flow cytometry. Increasing doses of ARA-C induced increased annexin V-positive cells
consistent with apoptosis.
(C) We treated four different carcinoma cell lines with ARA-C in a dose–response series for 6 d. Cell viability was evaluated with an ATP-based assay and
plotted relative to control cells. Error bars show standard deviation across four replicates.
doi:10.1371/journal.pmed.0040122.g004
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ARA-C Identified as an EWS/FLI Modulatordifference in the effects of RNAi directed against EWS/FLI
versus ARA-C treatment in A673 may be explained by the
inability of the shRNAs to completely ablate EWS/FLI
expression. Indeed, we note that it is difﬁcult to maintain
long-term knockdown of EWS/FLI, suggesting that there is
strong negative selection for EWS/FLI-ablated cells. We also
note that Prieur et al. [12] have reported that two rounds of
siRNA-mediated knockdown of EWS/FLI does in fact induce
apoptosis. Lastly, it is certainly possible (if not likely) that
ARA-C has additional cytotoxic effects independent of its
effect on EWS/FLI expression. ARA-C is a known nucleoside
analogue, which is transported inside cells and then phos-
phorylated to the triphosphate form by deoxycytidine kinase.
The incorporation of phosphorylated ARA-C into DNA
inhibits further DNA synthesis and causes death by apoptosis
[30].
ARA-C is not generally considered an agent that interferes
with protein synthesis or enhances degradation. We have
shown with real-time PCR that ARA-C is not decreasing
transcript as the mechanism of the decrease in EWS/FLI
protein. A second possibility is that ARA-C inhibits protein
synthesis by a mechanism not well characterized. A third
possibility is that ARA-C increases the degradation of EWS/
FLI. Interestingly, doxorubicin, a chemotherapy agent that is
the backbone of current Ewing sarcoma therapy, also
decreased EWS/FLI protein and induced the EWS/FLI off
gene expression signature, and rapamycin, an mTOR
inhibitor previously reported to decrease EWS/FLI protein,
induces an EWS/FLI off signature. Whether this is a universal
Figure 5. ARA-C Abrogates Anchorage-Independent Growth, a Hallmark
of Oncogenic Transformation
(A) ARA-C at 30 nM attenuates anchorage-independent growth as
assessed by a soft agar assay and abrogates it at 60 nM as does shRNA
against the EWS/FLI translocation.
(B) ARA-C at 30 and 60 nM dosing decreases mean cumulative
population doubling time by only 18% and 32%, respectively, at day
15. Error bars show the standard deviation across three replicates.
doi:10.1371/journal.pmed.0040122.g005
Figure 6. In vivo Efficacy of ARA-C in a Mouse Model of Ewing Sarcoma
(A) A673-Luciferase-positive xenografts were established for 2–3 wk in
NCr nude mice, with tumor burden monitored by bioluminescence
imaging. Mice with logarithmically growing tumors were treated with
intraperitoneal injection of ARA-C at 50 mg/kg daily for four doses or
vehicle control. In both a pilot experiment A: and a larger study with
cohorts of nine mice in each group B: control mice continued to have
logarithmic tumor growth, necessitating sacrifice within 1 wk of starting
treatments. By comparison, ARA-C-treated mice had stable disease or
tumor regression with seven of nine animals showing regression.
(B) Arrows indicate days of drug dosing, and the asterisk indicates p ,
0.05 by Student’s t-test (two-tailed assuming samples with equal
variance). Error bars show the standard deviation across nine replicates.
Bioluminescence was measured as photonic flux through standardized
regions of interest (photons per second per region of interest), which did
not include reflected light along the left flank (e.g., right animal in part
[A] at day 17 of ARA-C treatment).
doi:10.1371/journal.pmed.0040122.g006
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ARA-C Identified as an EWS/FLI Modulatorphenomenon shared in common by clinically effective drugs
for Ewing sarcoma is yet to be determined. Certainly it will be
of interest to establish the mechanism by which ARA-C
regulates EWS/FLI protein abundance, but given ARA-C’s
well-characterized safety proﬁle, these ﬁndings are of
immediate clinical relevance for a disease where relapse is
nearly always incurable.
The EC50 level of ARA-C (50–280 nM) is well below
clinically achievable serum levels in humans. With high dose
ARA-C (3 g/m
2/dose every 12 h), serum levels up to 40 lM
ARA-C are obtained, at 2 g/m
2/day, 5-lM levels are obtained,
and at 200 mg/m
2/day, 100–500-nM levels are obtained [30].
Currently, there is no curative therapy for patients with
recurrent Ewing sarcoma, and much room remains for
improvement in the treatment of patients with newly
diagnosed disease, particularly those with metastases. There
is a long experience of treating patients, both adults and
children, with AML and acute lymphoblastic leukemia with
ARA-C, with established dosing regimens and well-charac-
terized toxicity proﬁles [31–33]. We therefore believe that
clinical trials testing ARA-C in patients with Ewing sarcoma
are warranted.
We have demonstrated that development of expression-
based small-molecule library screening enables identiﬁcation
of modulators of important oncoproteins previously consid-
ered undruggable. Furthermore, it identiﬁed an already FDA-
approved candidate that can now be brought to clinical trial
for children with Ewing sarcoma. A national clinical trial to
test ARA-C in patients with relapsed Ewing sarcoma is
currently in development. In principle, this approach can be
utilized to identify modulators of any oncoprotein, simply by
deﬁning a signature of the oncoprotein’s activity. With an
ever-expanding list of ‘‘undruggable’’ oncoproteins critical in
the development of cancer, such as the discovery of ETS
transcription factor rearrangements in the majority of
patients with prostate cancer [34,35], it will be increasingly
important to explore alternative small-molecule discovery
platforms. GE-HTS provides an avenue for identifying tool
compounds for the study of these genetic lesions.
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Editors’ Summary
Background. Cancer occurs when cells accumulate genetic changes
(mutations) that allow them to divide uncontrollably and to travel
throughout the body (metastasize). Chemotherapy, a mainstay of cancer
treatments, works by killing rapidly dividing cells. Because some normal
tissues also contain dividing cells and are therefore sensitive to
chemotherapy drugs, it is hard to treat cancer without causing serious
side effects. In recent years, however, researchers have identified some of
the mutations that drive the growth of cancer cells. This raises the
possibility of designing drugs that kill only cancer cells by specifically
targeting ‘‘oncoproteins’’ (the abnormal proteins generated by muta-
tions that transform normal cells into cancer cells). Some ‘‘targeted’’
drugs have already reached the clinic, but unfortunately medicinal
chemists do not know how to inhibit the function of many classes of
oncoproteins with the small organic molecules that make the best
medicines. One oncoprotein in this category is EWS/FLI. This contains
part of a protein called EWS fused to part of a transcription factor (a
protein that controls cell behavior by telling the cell which proteins to
make) called FLI. About 80% of patients with Ewing sarcoma (the second
commonest childhood cancer of bone and soft tissue) have the mutation
responsible for EWS/FLI expression. Localized Ewing sarcoma can be
treated with nontargeted chemotherapy (often in combination with
surgery and radiotherapy), but treatment for recurrent or metastatic
disease remains very poor.
Why Was This Study Done? Researchers have known for years that
EWS/FLI expression drives the development of Ewing sarcoma by
activating the expression of target genes needed for tumor formation.
However, EWS/FLI has never been exploited as a target for therapy of
this cancer—mainly because traditional approaches used to screen
libraries of small molecules do not identify compounds that modulate
the activity of transcription factors. In this study, the researchers have
used a new gene expression–based, high-throughput screening (GE-HTS)
approach to identify compounds that modulate the activity of EWS/FLI.
What Did the Researchers Do and Find? The researchers used a
molecular biology technique called microarray expression profiling to
define a 14-gene expression signature that differentiates between Ewing
sarcoma cells in which the EWS/FLI fusion protein is active and those in
which it is inactive. They then used this signature to screen a library of
about 1,000 chemicals (many already approved for other clinical uses) in
a ‘‘ligation-mediated amplification assay.’’ For this, the researchers grew
Ewing sarcoma cells with the test chemicals, extracted RNA from the
cells, and generated a DNA copy of the RNA. They then added two short
pieces of DNA (probes) specific for each signature gene to the samples.
In samples that expressed a given signature gene, both probes bound
and were then ligated (joined together) and amplified. Because one of
each probe pair also contained a unique ‘‘capture sequence,’’ the
signature genes expressed in each sample were finally identified by
adding colored fluorescent beads, each linked to DNA complementary to
a different capture sequence. The most active modulator of EWS/FLI
activity identified by this GE-HTS approach was cytosine arabinoside
(ARA-C). At levels achievable in people, this compound reduced the
abundance of EWS/FLI protein in and the viability and cancer-like
behavior of Ewing sarcoma cells growing in test tubes. ARA-C treatment
also slowed the growth of Ewing sarcoma cells transplanted into mice.
What Do These Findings Mean? These findings identify ARA-C, which is
already used to treat children with some forms of leukemia, as a potent
modulator of EWS/FLI activity. More laboratory experiments are needed
to discover how ARA-C changes the behavior of Ewing sarcoma cells.
Nevertheless, given the poor outcomes currently seen in many patients
with Ewing sarcoma and the historical reluctance to test new drugs in
children, these findings strongly support the initiation of clinical trials of
ARA-C in children with Ewing sarcoma. These results also show that the
GE-HTS approach is a powerful way to identify candidate drugs able to
modulate the activity of some of the oncoproteins (including tran-
scription factors and other previously intractable targets) that drive
cancer development.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040122.
  Cancerquest from Emory University, provides information on cancer
biology (also includes information in Spanish, Chinese and Russian)
  The MedlinePlus encyclopedia has pages on Ewing sarcoma
  Information for patients and health professionals on Ewing sarcoma is
available from the US National Cancer Institute
  Cancerbackup offers information for patients and their parents on
Ewing sarcoma
  Wikipedia has pages on DNA microarrays and expression profiling
(note that Wikipedia is a free online encyclopedia that anyone can
edit)
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